25.06.2012 • NewsHovionesales and profitsQ1 2012

Hovione's Sales Grow 24%

Hovione announced that the consolidated sales for the fiscal year ended March 2012 amounted to $180 million, the sixth consecutive year of sales growth, representing a growth of 24% in relation to last year.

In addition to the financial results, which reflect the quality of the Team's performance, overall 2011 represented a year of great achievements, namely:

Hovione stood behind 3 NDA approvals, these were all major NMEs - and in two cases the approvals were full QbD filings in which Hovione was central to the design and data generation.

All Hovione plants underwent several successful GMP inspections by one or more of the major Medicines' Agencies - a reflection of the large flow of filings and the high standards of compliance.

 

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.